Compare ALNT & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALNT | NBTX |
|---|---|---|
| Founded | 1962 | 2003 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.0B |
| IPO Year | 1995 | 2018 |
| Metric | ALNT | NBTX |
|---|---|---|
| Price | $65.96 | $43.61 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $64.50 | $36.00 |
| AVG Volume (30 Days) | ★ 157.9K | 56.8K |
| Earning Date | 05-06-2026 | 03-31-2026 |
| Dividend Yield | ★ 0.16% | N/A |
| EPS Growth | ★ 67.09 | N/A |
| EPS | ★ 0.32 | N/A |
| Revenue | ★ $554,478,000.00 | N/A |
| Revenue This Year | $7.53 | $58.17 |
| Revenue Next Year | $6.64 | N/A |
| P/E Ratio | $206.75 | ★ N/A |
| Revenue Growth | ★ 4.62 | N/A |
| 52 Week Low | $29.25 | $3.64 |
| 52 Week High | $80.39 | $44.46 |
| Indicator | ALNT | NBTX |
|---|---|---|
| Relative Strength Index (RSI) | 41.29 | 70.10 |
| Support Level | $57.71 | $20.11 |
| Resistance Level | $67.79 | N/A |
| Average True Range (ATR) | 3.65 | 2.00 |
| MACD | -1.04 | 1.08 |
| Stochastic Oscillator | 26.29 | 94.53 |
Allient Inc, formerly Allied Motion Technologies Inc designs, manufactures, and sells precision and specialty controlled motion components and systems. The firm mainly caters to the Industrial, Vehicle, Aerospace & Defense, and Medical sectors. It mainly operates and sells across the United States, Canada, South America, Europe, and Asia. Its products and solutions include nano precision positioning systems, servo control systems, motion controllers, digital servo amplifiers and drives, brushless servo, torque, and coreless motors, brush motors, integrated motor drives, gear motors, gearing, incremental and absolute optical encoders, active (electronic) and passive (magnetic) filters for power quality and harmonic issues.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.